Ascendis Pharma (ASND) Misses Q4 EPS by 40c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR0.55), EUR0.40 worse than the analyst estimate of (EUR0.15). Revenue for the quarter came in at EUR240 million versus the consensus estimate of EUR245.68 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Deere shares climb as fiscal Q3 earnings and revenue top estimates
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• IDEXX Laboratories (IDXX) Reiterated at Buy by Stifel as Fundamentals Remain Intact